Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency.

C Cunningham-Rundles1, C Bodian, H D Ochs

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA. charlotte.cunningham-rundles@mssm.edu

Clinical Immunology (Orlando, Fla.)
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rheumatologic diseases in patients with inborn errors of immunity in the USIDNET registry.

Clinical rheumatology·2022
Same author

Gut T cell-independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells.

Science immunology·2020
Same author

Chemical chaperones reverse early suppression of regulatory circuits during unfolded protein response in B cells from common variable immunodeficiency patients.

Clinical and experimental immunology·2019
Same author

Loss of B Cells in Patients with Heterozygous Mutations in IKAROS.

The New England journal of medicine·2016
Same author

7th International Immunoglobulin Conference: Immunodeficiencies.

Clinical and experimental immunology·2014
Same author

Common variable immunodeficiency (CVID): new genetic insight and unanswered questions.

Clinical and experimental immunology·2014
Same journal

A novel JAK1 mutation identified in a patient with severe atopic dermatitis phenotype: Mechanistic insights and IL-4Rα targeted therapy.

Clinical immunology (Orlando, Fla.)·2026
Same journal

VNN1 aggravates sepsis by promoting inflammation and oxidative stress through PPARγ signaling VNN1 in sepsis.

Clinical immunology (Orlando, Fla.)·2026
Same journal

Comparison between glioblastoma and brain metastases: How epigenetic remodeling can enhance immunotherapy.

Clinical immunology (Orlando, Fla.)·2026
Same journal

JAK-STAT3-MYC axis defines pathogenic stem cell-like memory CD4<sup>+</sup> T cells in rheumatoid arthritis.

Clinical immunology (Orlando, Fla.)·2026
Same journal

The baseline vaginal immune milieu is an important determinant of the inflammatory response induced by penile-vaginal sex.

Clinical immunology (Orlando, Fla.)·2026
Same journal

Adulthood diagnosis of Nijmegen breakage syndrome in twins with antibody deficiency clinical presentation.

Clinical immunology (Orlando, Fla.)·2026
See all related articles

Interleukin-2 (IL-2) therapy improved T cell function in patients with common variable immunodeficiency (CVID). This treatment enhanced immune responses and may help reverse T cell anergy in CVID patients.

Area of Science:

  • Immunology
  • Clinical Medicine
  • Biotechnology

Background:

  • Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by hypogammaglobulinemia and impaired antibody production.
  • T cell defects, including reduced IL-2 expression, are observed in CVID patients.
  • Investigating IL-2 as a therapeutic agent is crucial for understanding and treating CVID.

Purpose of the Study:

  • To evaluate the efficacy of a long-acting form of IL-2 (PEG-IL-2) in treating CVID.
  • To assess the impact of IL-2 treatment on T cell function and immune responses in CVID subjects.
  • To determine if IL-2 can serve as an adjuvant therapy for CVID.

Main Methods:

  • A randomized trial involving 15 CVID subjects treated with PEG-IL-2 for 12-18 months.

Related Experiment Videos

  • Comparison of outcomes with 39 CVID subjects serving as controls.
  • Assessment of T cell proliferative responses to mitogens, IL-2, and antigens, as well as antibody production after immunization.

    • Main Results:

    • Significant enhancement of T cell proliferative responses to mitogens and IL-2 after 6-12 months of treatment.
    • Up to 50-fold increase in proliferative responses to tetanus and candida antigens.
    • Increased antibody responses in 4 out of 8 subjects immunized with bacteriophage φX 174; reduced days of bronchitis, diarrhea, and joint pain observed.

    Conclusions:

    • In vivo IL-2 treatment can significantly enhance T cell functions in CVID patients.
    • PEG-IL-2 may reverse T cell anergy and act as an adjuvant therapy for some CVID subjects.
    • Further research is warranted to optimize IL-2-based therapies for primary immunodeficiencies.